Paul Antoni, Ko Kerry W S, Li Lan, Yechoor Vijay, McCrory Mark A, Szalai Alexander J, Chan Lawrence
Division of Diabetes, Endocrinology & Metabolism, Department of Medicine, Baylor College of Medicine, Houston, Tex 77030, USA.
Circulation. 2004 Feb 10;109(5):647-55. doi: 10.1161/01.CIR.0000114526.50618.24. Epub 2004 Jan 26.
Plasma C-reactive protein (CRP) concentration is a strong predictor of atherosclerosis. However, to date, there is no in vivo evidence that CRP is proatherogenic.
We studied the effect of human CRP transgene (tg) expression, under basal and turpentine-stimulated conditions, on atherosclerosis in apolipoprotein (apo) E-/- mice. Aortic atherosclerotic lesions in 29-week-old male mice were 48% larger (P<0.02) in turpentine-treated mice and 34% larger (P<0.05) in untreated CRPtg+/0/apoE-/- mice. Turpentine treatment per se did not affect the extent of atherosclerosis in CRP transgenic or nontransgenic apoE-/- mice. Transgenic mice exhibited lower plasma complement C3 but increased deposition of CRP and C3 in the lesions, which suggests that CRP stimulated activation of complement within the lesion. There was more intense and widespread vascular cell adhesion molecule-1 and collagen staining in the lesions of CRPtg+/0/apoE-/- mice than in CRPtg0/0/apoE-/- littermates. Lesions of CRPtg+/0/apoE-/- mice contained increased angiotensin type 1 receptor (AT1-R) transcripts and displayed increased AT1-R immunostaining compared with those of CRPtg0/0/apoE-/- mice. There was no difference in blood pressure in the 2 types of mice, which indicates that the proatherogenic effect of CRP-associated AT1-R overexpression is local and not mediated by its hypertensive properties.
Human CRP transgene expression causes accelerated aortic atherosclerosis in apoE-/- mice. CRP was detected in the lesion, which was associated with increased C3 deposition and increased AT1-R, vascular cell adhesion molecule-1, and collagen expression. These data document a proatherogenic role for CRP in vivo.
血浆C反应蛋白(CRP)浓度是动脉粥样硬化的一个强有力的预测指标。然而,迄今为止,尚无体内证据表明CRP具有促动脉粥样硬化作用。
我们研究了在基础状态和松节油刺激条件下,人CRP转基因(tg)表达对载脂蛋白(apo)E基因敲除(-/-)小鼠动脉粥样硬化的影响。在29周龄雄性小鼠中,经松节油处理的小鼠主动脉粥样硬化病变面积增大48%(P<0.02),未经处理的CRP转基因杂合子(+/0)/apoE-/-小鼠病变面积增大34%(P<0.05)。松节油处理本身对CRP转基因或非转基因apoE-/-小鼠的动脉粥样硬化程度无影响。转基因小鼠血浆补体C3水平较低,但病变部位CRP和C3沉积增加,这表明CRP刺激了病变部位补体的激活。与CRP基因敲除纯合子(0/0)/apoE-/-同窝小鼠相比,CRP转基因杂合子(+/0)/apoE-/-小鼠病变部位血管细胞黏附分子-1和胶原蛋白染色更强烈且更广泛。与CRP基因敲除纯合子(0/0)/apoE-/-小鼠相比,CRP转基因杂合子(+/0)/apoE-/-小鼠病变部位血管紧张素1型受体(AT1-R)转录本增加,AT1-R免疫染色增强。两种小鼠的血压无差异,这表明CRP相关的AT1-R过表达的促动脉粥样硬化作用是局部的,而非由其高血压特性介导。
人CRP转基因表达导致apoE-/-小鼠主动脉粥样硬化加速。在病变部位检测到CRP,其与C3沉积增加以及AT1-R、血管细胞黏附分子-1和胶原蛋白表达增加有关。这些数据证明了CRP在体内具有促动脉粥样硬化作用。